Quantcast

Industry news that matters to you.  Learn more

N-of-One Selected by Admera Health to Provide Clinical Interpretation for the OncoGxOne 64-Gene Oncology Panel

N-of-One, Inc., the leader in clinical interpretation of molecular tests in oncology, recently announced that Admera Health, a molecular diagnostics company focused on personalized medicine and non-invasive cancer testing, has selected N-of-One to provide clinical interpretation of their 64-gene oncology panel, OncoGxOne™. N-of-One’s patient-specific analysis is based on the clinical and scientific evidence linking the results of each patient’s molecular tests to therapeutic strategies, including clinical trials. Financial terms of the agreement are not disclosed.

QIAGEN Expands Clinical Decision Support for NGS in Oncology Labs

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced enhancements to its QIAGEN Clinical Insight® (QCI™) clinical decision support solution, which streamlines the annotation, interpretation and reporting of next-generation sequencing results (NGS) for clinical laboratories.

Leading Oncology Researchers Address Growing Need for Assessing Tumor Microenvironment in Cancer Research

Key professionals in leading biopharma organizations attended The International Symposium for Tissue Phenomics™ in October 2014 to discuss the latest developments in cancer research and big data. Hosted by Definiens, the global leader in Tissue Phenomics for oncology diagnostics, the event drew key industry professionals and featured speakers from cutting edge organizations such as INSERM, National Cancer Institute, Kimmel Cancer Center, Providence Health Services, OncoMed Pharmaceuticals and University Medical Center Heidelberg. Presentations highlighted novel, important approaches in cancer research for the development of companion diagnostics, analysis of data, and validation of assays used to drive therapies.

Surveyed European Oncologists Indicate that Predictive Biomarkers that Identify Patients Most Likely to Respond to Therapies Are a Clear Advantage for Costly Oncology Drugs

Decision Resources Group finds that biomarker driven prescribing is likely to positively influence perceptions of oncology drugs for both oncologists and payers. Drawing on insights from over 300 surveyed medical oncologists and 15 interviewed payers across the EU5 (FranceGermanyItalySpain, and the United Kingdom), the findings reveal that although an increase in biomarker testing is seen as a likely future event, the incorporation of additional biomarker tests (e.g. PD-L1 expression for non-small-cell lung cancer) into the diagnosis could prove challenging in cost-conscious countries like ItalySpain, and the United Kingdom. Overall, however, surveyed physicians and interviewed payers are universal in their opinion that the market access of a costly novel agent would be significantly aided by the presence of a companion biomarker test. 

Definiens to Host the First International Symposium for Tissue Phenomics This Fall

Definiens, the global leader in Tissue Phenomics™ for oncology diagnostics, recently announced that registration is now open for the company’s inaugural conference, The International Symposium for Tissue Phenomics. Alongside genomics, Tissue Phenomics is a key driver in the growth of personalized medicine, and the symposium brings together thought leaders from around the globe on companion diagnostics, immunotherapy, and tissue-based patient stratification for personalized medicine. The Symposium will begin with a keynote lecture from Nobel Laureate, Gerd Binnig, Ph.D., discussing his approach to uncovering novel diagnostics through using big data in tissue.